Unknown

Dataset Information

0

Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC4812840 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
| S-EPMC10147634 | biostudies-literature
Unknown A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
| S-EPMC3173448 | biostudies-literature
Unknown Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
| S-EPMC5329168 | biostudies-literature
Unknown A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.
| S-EPMC10284878 | biostudies-literature
Unknown Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.
| S-EPMC10579797 | biostudies-literature
Unknown Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.
| S-EPMC11532157 | biostudies-literature
Unknown Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
| S-EPMC4000321 | biostudies-literature
Unknown Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
| S-EPMC9673291 | biostudies-literature
Unknown First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
| S-EPMC7956424 | biostudies-literature
Unknown CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
| S-EPMC8405627 | biostudies-literature